Home  »  Markets   »  New Big Money Means Ascendis Pharma A/S (ASND) Inv...

New Big Money Means Ascendis Pharma A/S (ASND) Investors Could Reap Benefit

249 institutions hold shares in Ascendis Pharma A/S (ASND), with 13.97k shares held by insiders accounting for 0.03% while institutional investors hold 103.11% of the company’s shares. The shares outstanding are 53.52M, and float is at 43.77M with Short Float at 6.88%. Institutions hold 103.09% of the Float.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Price (T.Rowe) Associates Inc with over 6.62 million shares valued at $1.1 billion. The investor’s holdings represent 12.31% of the ASND Shares outstanding. As of Dec 30, 2020, the second largest holder is RA Capital Management, L.P. with 5.87 million shares valued at $978.22 million to account for 10.91% of the shares outstanding. The other top investors are Artisan Partners Limited Partnership which holds 5.77 million shares representing 10.73% and valued at over $961.91 million, while FMR, LLC holds 9.94% of the shares totaling 5.34 million with a market value of $890.87 million.

Ascendis Pharma A/S (NASDAQ: ASND) is -14.88% lower on its value in year-to-date trading and has touched a low of $119.11 and a high of $183.98 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ASND stock was last observed hovering at around $138.27 in the last trading session, with the day’s gains setting it 3.69% off its average median price target of $158.86 for the next 12 months. It is also 21.54% off the consensus price target high of $180.93 offered by 14 analysts, but current levels are -1.67% lower than the price target low of $139.63 for the same period.

Currently trading at $141.96, the stock is 10.36% and 1.94% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.22 million and changing 2.67% at the moment leaves the stock -6.41% off its SMA200. ASND registered 6.16% gain for a year compared to 6-month loss of -13.56%. The firm has a 50-day simple moving average (SMA 50) of $132.92 and a 200-day simple moving average (SMA200) of $154.55.

The stock witnessed a 10.35% gain in the last 1 month and extending the period to 3 months gives it a -8.64%, and is 7.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.65% over the week and 3.56% over the month.

Ascendis Pharma A/S (ASND) has around 482 employees, a market worth around $7.62B and $8.40M in sales. Distance from 52-week low is 19.18% and -22.84% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.50%).

Ascendis Pharma A/S (ASND) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Ascendis Pharma A/S (ASND) is a “Buy”. 14 analysts offering their recommendations for the stock have an average rating of 1.60, where 1 rate it as a Hold and 0 think it is a “Overweight”. 13 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Ascendis Pharma A/S is expected to release its quarterly report on 09/01/2021 and quarterly earnings per share for the current quarter are estimated at -$2.07 with sales reaching $2.28M over the same period.The EPS is expected to shrink by -76.60% this year, but quarterly earnings will post 253.50% year-over-year. Quarterly sales are estimated to grow 8.10% in year-over-year returns.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Ascendis Pharma A/S (ASND): Who are the competitors?

The company’s main competitors (and peers) include Agenus Inc. (AGEN) that is trading 12.77% up over the past 12 months. Amgen Inc. (AMGN) is -0.42% down on the 1-year trading charts. Short interest in the company’s stock has fallen -5.61% from the last report on Apr 14, 2021 to stand at a total of 3.01 million short shares sold with a short interest ratio of 12.44.

Related Posts




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam